Curing Operable Stage I Non-Small Cell Lung Cancer With Stereotactic Ablative Body Radiotherapy: The Force Awakens

In 2016, surgery is the standard of care for peripheral stage I non-small cell lung cancer. However, recent thought-provoking randomized evidence suggests stereotactic ablative body radiotherapy (SABR) has survival outcomes similar to those of surgery. Albeit limited, patient-reported outcomes and q...

Descripción completa

Detalles Bibliográficos
Autores principales: Siva, Shankar, Ball, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2016
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4828125/
https://www.ncbi.nlm.nih.gov/pubmed/26984447
http://dx.doi.org/10.1634/theoncologist.2015-0477
_version_ 1782426544528949248
author Siva, Shankar
Ball, David
author_facet Siva, Shankar
Ball, David
author_sort Siva, Shankar
collection PubMed
description In 2016, surgery is the standard of care for peripheral stage I non-small cell lung cancer. However, recent thought-provoking randomized evidence suggests stereotactic ablative body radiotherapy (SABR) has survival outcomes similar to those of surgery. Albeit limited, patient-reported outcomes and quality of life suggest that SABR compares favorably to surgery because it is noninvasive and associated with relatively few treatment-related complications. This article explores the current scientific landscape of surgery and SABR in this patient cohort.
format Online
Article
Text
id pubmed-4828125
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher AlphaMed Press
record_format MEDLINE/PubMed
spelling pubmed-48281252016-07-14 Curing Operable Stage I Non-Small Cell Lung Cancer With Stereotactic Ablative Body Radiotherapy: The Force Awakens Siva, Shankar Ball, David Oncologist Editorial In 2016, surgery is the standard of care for peripheral stage I non-small cell lung cancer. However, recent thought-provoking randomized evidence suggests stereotactic ablative body radiotherapy (SABR) has survival outcomes similar to those of surgery. Albeit limited, patient-reported outcomes and quality of life suggest that SABR compares favorably to surgery because it is noninvasive and associated with relatively few treatment-related complications. This article explores the current scientific landscape of surgery and SABR in this patient cohort. AlphaMed Press 2016-04 2016-03-16 /pmc/articles/PMC4828125/ /pubmed/26984447 http://dx.doi.org/10.1634/theoncologist.2015-0477 Text en ©AlphaMed Press
spellingShingle Editorial
Siva, Shankar
Ball, David
Curing Operable Stage I Non-Small Cell Lung Cancer With Stereotactic Ablative Body Radiotherapy: The Force Awakens
title Curing Operable Stage I Non-Small Cell Lung Cancer With Stereotactic Ablative Body Radiotherapy: The Force Awakens
title_full Curing Operable Stage I Non-Small Cell Lung Cancer With Stereotactic Ablative Body Radiotherapy: The Force Awakens
title_fullStr Curing Operable Stage I Non-Small Cell Lung Cancer With Stereotactic Ablative Body Radiotherapy: The Force Awakens
title_full_unstemmed Curing Operable Stage I Non-Small Cell Lung Cancer With Stereotactic Ablative Body Radiotherapy: The Force Awakens
title_short Curing Operable Stage I Non-Small Cell Lung Cancer With Stereotactic Ablative Body Radiotherapy: The Force Awakens
title_sort curing operable stage i non-small cell lung cancer with stereotactic ablative body radiotherapy: the force awakens
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4828125/
https://www.ncbi.nlm.nih.gov/pubmed/26984447
http://dx.doi.org/10.1634/theoncologist.2015-0477
work_keys_str_mv AT sivashankar curingoperablestageinonsmallcelllungcancerwithstereotacticablativebodyradiotherapytheforceawakens
AT balldavid curingoperablestageinonsmallcelllungcancerwithstereotacticablativebodyradiotherapytheforceawakens

Ejemplares similares